Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/ CTAD Task Force

Alzheimer's and Dementia

Volumn 9, Issue 4, 2013, Pages 438-444

  Vellas, Bruno ^a,b,c   Carrillo, Maria C ^x   Sampaio, Cristina ^e   Brashear, H Robert ^f   Siemers, Eric ^g   Hampel, Harald ^h   Schneider, Lon S ⁱ   Weiner, Michael ^j   Doody, Rachelle ^k   Khachaturian, Zaven ^l   Cedarbaum, Jesse ^m   Grundman, Michael ⁿ   Broich, Karl ^o   Giacobini, Ezio ^p   Dubois, Bruno ^s   Sperling, Reisa ^q   Wilcock, Gordon K ^r   Fox, Nick ^t   Scheltens, Philip ^u   Touchon, Jacques ^v   Hendrix, Suzanne ^w   Andrieu, Sandrine ^a,b,c   Aisen, Paul ^d   more..

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^f Janssen AI   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h GOETHE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l Campaign to Prevent Alzheimer's Disease by 2020 ^*  (United States)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ Global R and D Partners LLC   (United States)

^o Fed Inst Drugs and Med Devices   (Germany)

^p UNIVERSITY OF GENEVA   (Switzerland)

^q BRIGHAM AND WOMEN S HOSPITAL   (United States)

^r UNIVERSITY OF OXFORD   (United Kingdom)

^s INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^t UNIVERSITY COLLEGE LONDON   (United Kingdom)

^u VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^v MONTPELLIER UNIVERSITY HOSPITAL   (France)

^w Pentara Corporation   (United States)

^x ALZHEIMER'S ASSOCIATION   (United States)

more..

Author keywords

Alzheimer's disease; Clinical trials; Pharmacotherapy

Indexed keywords

BAPINEUZUMAB; BIOLOGICAL MARKER; PLACEBO; SOLANEZUMAB;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COGNITION; DEMENTIA; DOWNSTREAM PROCESSING; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EARLY INTERVENTION; EDEMA; HUMAN; MONACO; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; STUDY DESIGN; TREATMENT PLANNING;

EID: 84882308754     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.03.007     Document Type: Article

References (20)

1. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70.
2. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72.
3. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 2012;11:241-9.
4. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-46.
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimers Dement 2011;7:280-92.
6. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83.
7. FolsteinMF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-98.
8. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74.
9. Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med 2010;16:1218-22.
10. Frisoni GB, Jack CR. Harmonization of magnetic resonance-based manual hippocampal segmentation: A mandatory step for wide clinical use. Alzheimers Dement 2011;7:171-4.
11. Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, et al. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. Biomark Med 2012;6:401-7.
12. Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: Definitions and approaches with focus on amyloid beta42. Biomark Med 2012; 6:409-17.
13. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9:119-28.
14. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network. N Engl J Med 2012; 367:795-804.
15. Tosun D, Joshi S, Weiner M. Alzheimer's Disease Neuroimaging Initiative: Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol 2013 [in press].
16. Tosun D, Weiner M. Alzheimer's Disease Neuroimaging Initiative: Neuromorphometry predictors of amyloid-beta positivity in individuals with MCI. Paper presented at: Alzheimer's Association International Conference, Vancouver, British Columbia, Canada, 2012.
17. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med 2005;24:329-39.
18. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarkerdefined subset effect. J Natl Cancer Inst 2007;99:1036-43.
19. Freidlin B, Simon R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005; 11:7872-8.
20. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): A randomised placebo-controlled trial. Lancet Neurol 2012;11:851-9.